(3aR*,6aS*)-3-(2-Methoxyethyl)-6a-methyl-6-phenylhexahydro-
[1,2]dioxolo[3,4-b]pyrrole (1k)
Acknowledgements
We are grateful to the Centre National de la Recherche Scientifique
and to the Muse´um National d¢Histoire Naturelle for financial
support. We also wish to thank the people of the HPLC, mass
spectrometry and elemental analysis services of the Institut de
Chimie des Substances Naturelles for their contribution to this
work.
This compound was prepared from endo-2k (30.0 mg, 130 mmol) by
applying the general procedure C (+0.65 V during 30 min). Anal-
ysis of the crude product (yellow oil) by 1H NMR spectroscopy15
revealed the presence of the two diastereoisomeric endoperoxide
products endo-1k (29.1%) and exo-1k (29.3%), i.e. an overall
estimated yield of 58% and an endo/exo ratio of 50 : 50. Flash
chromatography (neutral alumina, activity II, AcOEt/heptane,
gradient from 0% to 10%) led to the isolation of partially purified
endo-1k (4.1 mg), contaminated with two vinylogous amides 6 and
7 (endo-1k/6/7 ratio 37 : 40 : 23), that were not present in the crude
Notes and references
1 Reviews: (a) O. G. Kulinkovich and A. de Meijere, Chem. Rev.,
2000, 100, 2789–2834; (b) A. de Meijere, S. I. Kozhushkov, and
A. I. Savchenko, in Titanium and Zirconium in Organic Synthesis, ed.
I. Marek, Wiley-VCH, Weinheim, 2002, pp 390-434; (c) A. de Meijere,
S. I. Kozhushkov and A. I. Savchenko, J. Organomet. Chem., 2004, 689,
2033–2055; (d) A. Wolan and Y. Six, Tetrahedron, 2010, 66, 15–61.
2 C. Madelaine, Y. Six and O. Buriez, Angew. Chem., 2007, 119, 8192–
8195; C. Madelaine, Y. Six and O. Buriez, Angew. Chem., Int. Ed., 2007,
46, 8046–8049.
1
product as verified by H NMR. Attempted further purification
by preparative HPLC [(H2O + 0.1% HCO2H)/(MeOH + 0.1%
HCO2H) 50 : 50, flow rate 17 mL min-1, UV detection 254 nm]
only led to the isolation of pure 6 (1.5 mg, 6.1 mmol, 5%).
3 Selected papers and reviews: (a) J. Wiesner, R. Ortmann, H. Jomaa
and M. Schlitzer, Angew. Chem., 2003, 115, 5432–5451; J. Wiesner, R.
Ortmann, H. Jomaa and M. Schlitzer, Angew. Chem., Int. Ed., 2003,
42, 5274–5293; (b) A. Robert, F. Benoit-Vical and B. Meunier, Coord.
Chem. Rev., 2005, 249, 1927–1936; (c) P. A. Stocks, P. G. Bray, V. E.
Barton, M. Al-Helal, M. Jones, N. C. Araujo, P. Gibbons, S. A. Ward,
R. H. Hughes, G. A. Biagini, J. Davies, R. Amewu, A. E. Mercer, G.
Ellis and P. M. O’Neill, Angew. Chem., 2007, 119, 6394–6399; P. A.
Stocks, P. G. Bray, V. E. Barton, M. Al-Helal, M. Jones, N. C. Araujo,
P. Gibbons, S. A. Ward, R. H. Hughes, G. A. Biagini, J. Davies, R.
Amewu, A. E. Mercer, G. Ellis and P. M. O’Neill, Angew. Chem., Int.
Ed., 2007, 46, 6278–6283; (d) R. K. Haynes, W. C. Chan, C.-M. Lung,
A.-C. Uhlemann, U. Eckstein, D. Taramelli, S. Parapini, D. Monti and
S. Krishna, ChemMedChem, 2007, 2, 1480–1497; (e) M. H. Gelb, Curr.
Opin. Chem. Biol., 2007, 11, 440–445; (f) C. W. Jefford, Drug Discovery
Today, 2007, 12, 487–495; (g) K. M. Muraleedharan and M. A. Avery,
Drug Discovery Today, 2009, 14, 793–803.
endo-1k (3R*,3aS*,6aR*). Yellow oil; dH(300 MHz; CDCl3;
Me4Si) 1.57 (3 H, s), 1.89 (2 H, q, J 6.5), 1.93 (1 H, ddd, J 12.5,
8.5, 6.5 and 3.5), 2.10 (1 H, dddd, J 12.5, 9.0, 8.0 and 7.5), 3.11
(1 H, ddd, J 8.5, 7.5 and 5.0), 3.25–3.42 (1 H, m), 3.36 (3 H,
s), 3.45–3.55 (3 H, m), 4.47 (1 H, td, J 6.5 and 5.0), 6.84 (1 H,
t, J 7.5), 6.96 (2 H, d, J 8.5), 7.22 (2 H, dd, J 8.5 and 7.5);
dC(75.5 MHz; CDCl3; Me4Si) characteristic signals 49.2, 58.7,
62.0, 69.7, 81.3, 103.4, 116.8, 119.4, 128.7. This compound could
not be characterised more extensively because of the lack of purity
and the small amount obtained.
exo-1k (3R*,3aR*,6aS*). dH(300 MHz; CDCl3; Me4Si) char-
acteristic signals 1.63 (3 H, s), 2.97 (1 H, ddd, J 8.5, 5.0 and 2.0),
4.20 (1 H, ddd, J 9.0, 4.5 and 2.5); dC(75.5 MHz; CDCl3; Me4Si)
characteristic signals 20.1, 33.6, 49.2, 58.8, 65.0, 69.1, 85.3, 102.7,
116.8, 119.3, 128.7.
6. dH(300 MHz; CDCl3; Me4Si) 1.82 (3 H, s), 2.50 (2 H, t, J 7.5),
2.64 (2 H, t, J 6.0), 3.31 (3 H, s), 3.61 (2 H, t, J 6.0), 3.70 (2 H, t,
J 7.5), 7.17 (2 H, dd, J 7.5 and 1.5), 7.35 (1 H, tt, J 7.5 and 1.5),
7.42 (2 H, t, J 7.5).
7. dH(300 MHz; CDCl3; Me4Si) characteristic signals 2.30 (3 H,
t, J 1.0), 2.69 (2 H, t, J 6.5), 2.95 (2 H, tq, J 9.5 and 1.0), 3.38 (3
H, s), 3.75 (2 H, t, J 6.5), 3.93 (2 H, t, J 9.5), 7.17 (2 H, dd, J 7.5
and 1.5).
4 K. Wimalasena, H. B. Wickman and M. P. D. Mahindaratne,
Eur. J. Org. Chem., 2001, 3811–3817.
5 For recent examples of alternative methods for the synthesis of fused
bicyclic aminocyclopropane derivatives, see: (a) S. Couty, C. Meyer and
J. Cossy, Synlett, 2007, 2819–2822; (b) S. Couty, C. Meyer and J. Cossy,
Tetrahedron, 2009, 65, 1809–1832; (c) P. Bertus and J. Szymoniak, Org.
Lett., 2007, 9, 659–662; (d) A. Joosten, J.-L. Vasse, P. Bertus and J.
Szymoniak, Synlett, 2008, 2455–2458; (e) D. Astashko, H. G. Lee,
D. N. Bobrov and J. K. Cha, J. Org. Chem., 2009, 74, 5528–5532;
(f) P. K. Mykhailiuk, S. Afonin, G. V. Palamarchuk, O. V. Shishkin,
A. S. Ulrich and I. V. Komarov, Angew. Chem., 2008, 120, 5849–5851;
P. K. Mykhailiuk, S. Afonin, G. V. Palamarchuk, O. V. Shishkin, A. S.
Ulrich and I. V. Komarov, Angew. Chem., Int. Ed., 2008, 47, 5765–5767;
(g) S. Ouizem, The`se de l’Universite´ Pierre et Marie Curie, Paris, 2010.
6 Reviews: (a) J.-P. Be´gue´ and D. Bonnet-Delpon, J. Fluorine Chem.,
2006, 127, 992–1012; (b) K. L. Kirk, J. Fluorine Chem., 2006, 127, 1013–
1029; (c) J.-P. Be´gue´, and D. Bonnet-Delpon, In Chimie Bioorganique
et Me´dicinale du Fluor, EDP Sciences and CNRS Editions: Paris, 2005;
(d) J.-P. Be´gue´, and D. Bonnet-Delpon, (Transl. J. Legros), Bioorganic
and Medicinal Chemistry of Fluorine, John Wiley & Sons: Hoboken,
2008; (e) K. Mu¨ller, C. Faeh and F. Diederich, Science, 2007, 317,
1881–1886; (f) W. K. Hagmann, J. Med. Chem., 2008, 51, 4359–4369;
(g) K. L. Kirk, Org. Process Res. Dev., 2008, 12, 305–321.
7 (a) T. T. T. Nga, C. Me´nage, J.-P. Be´gue´, D. Bonnet-Delpon and J.-
C. Gantier, J. Med. Chem., 1998, 41, 4101–4108; (b) F. Grellepois,
F. Chorki, M. Oure´vitch, S. Charneau, P. Grellier, K. A. McIntosh,
W. N. Charman, B. Pradines, B. Crousse, D. Bonnet-Delpon and J.-P.
Be´gue´, J. Med. Chem., 2004, 47, 1423–1433; (c) G. Magueur, B. Crousse,
S. Charneau, P. Grellier, J.-P. Be´gue´ and D. Bonnet-Delpon, J. Med.
Chem., 2004, 47, 2694–2699; (d) C. Chollet, B. Crousse, M. Oure´vitch
and D. Bonnet-Delpon, J. Org. Chem., 2006, 71, 3082–3085; (e) For a
review, see:J.-P. Be´gue´ and D. Bonnet-Delpon, ChemMedChem, 2007,
2, 608–624.
Evaluation of the activity against Plasmodium falciparum
In vitro antimalarial assays were performed on human erythro-
cytes with the chloroquine-resistant FcB1 strain of Plasmodium
falciparum as described.22 Briefly, stock solutions of compounds,
prepared in DMSO, were serially diluted with culture medium and
introduced to asynchronous parasite cultures (1% parasitaemia
and 1% final hematocrite) on 96-well plates for 24 h at 37 ◦C
prior to the addition of 0.5 mCi of [3H]hypoxanthine per well,
for 24 h. The growth inhibition for each drug concentration was
determined by comparison of the radioactivity incorporated into
the treated culture with that in the control culture (without drug)
maintained on the same plate. The concentrations causing 50%
inhibition (IC50) or 90% inhibition (IC90) were obtained from the
drug concentration-response curves of triplicate experiments.
8 A. de Meijere, C. M. Williams, A. Kourdioukov, S. V. Sviridov,
V. Chaplinski, M. Kordes, A. I. Savchenko, C. Stratmann and M.
Noltemeyer, Chem.–Eur. J., 2002, 8, 3789–3801.
5600 | Org. Biomol. Chem., 2010, 8, 5591–5601
This journal is
The Royal Society of Chemistry 2010
©